Jump to content

Agatha Jassem

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by InternetArchiveBot (talk | contribs) at 11:56, 5 August 2023 (Rescuing 0 sources and tagging 2 as dead.) #IABot (v2.0.9.5). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Agatha Jassem
NationalityCanadian
Alma materUniversity of British Columbia
Occupationclinical microbiologist

Agatha Jassem is a Canadian clinical microbiologist and the program head of the Virology Lab at the British Columbia Centre for Disease Control Public Health Laboratory,[1] and a clinical assistant professor in the Department of Pathology & Laboratory Medicine at the University of British Columbia in Vancouver, British Columbia, Canada.[2]

Jassem obtained her PhD at the University of British Columbia, followed by a fellowship in Clinical Microbiology at the National Institutes of Health.[3] Her research focuses the detection of healthcare-and community-associated infections, emerging pathogens, and drug resistance determinants.

During the COVID-19 pandemic response, Jassem led research efforts on COVID-19 breakthrough infections from vaccinated individuals,[4][5] SARS-CoV-2 population level seroprevalence,[6] antibody response [7] as well as collaborating on research on securing reagents for COVID-19 during world-wide shortages,[8] and the role of ACEII. [9]

References

  1. ^ "Agatha Jassem". bccdc.ca. Retrieved 2021-09-20.
  2. ^ "Agatha Jassem". Pathology. Retrieved 2021-09-20.[permanent dead link]
  3. ^ "Agatha Jassem". Pathology. Retrieved 2021-09-20.[permanent dead link]
  4. ^ "COVID-19 Smiles – The Study of Vaccine Escape Mutants | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-09-20.
  5. ^ "COVID-19 research initiatives at UBC among those funded by first-time partnership". UBC Faculty of Medicine. 2021-05-21. Retrieved 2021-09-28.
  6. ^ "Population-Based Study Of Coronavirus Antibody Cross-Reactivity To Inform SARS-CoV-2 Seroprevalence | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-09-20.
  7. ^ "Characterizing Antibody Response to Emerging COVID-19 Virus (CARE COVID-19) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-09-20.
  8. ^ "Securing Reagent Supplies and Scaling COVID-19 | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-09-20.
  9. ^ "Prognostication of ACE II Receptor (PACEiiR) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-09-20.